173 related articles for article (PubMed ID: 33023953)
1. Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
Daemen A; Cooper JE; Myrta S; Wongchenko MJ; Lin E; Long JE; Foreman O; Modrusan Z; Tremayne JR; de la Cruz CC; Merchant M; Martin SE; Yan Y; Junttila MR
Clin Cancer Res; 2021 Feb; 27(4):1162-1173. PubMed ID: 33023953
[TBL] [Abstract][Full Text] [Related]
2. An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
Cheng C; Zhao Y; Schaafsma E; Weng YL; Amos C
Int J Cancer; 2020 Nov; 147(9):2621-2633. PubMed ID: 32406930
[TBL] [Abstract][Full Text] [Related]
3. PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition.
Meeusen B; Cortesi EE; Domènech Omella J; Sablina A; Ventura JJ; Janssens V
Cancer Lett; 2021 Nov; 520():57-67. PubMed ID: 34216687
[TBL] [Abstract][Full Text] [Related]
4. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
5. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
6. Single-cell transcriptome analysis demonstrates inter-patient and intra-tumor heterogeneity in primary and metastatic lung adenocarcinoma.
Liu Y; Ye G; Huang L; Zhang C; Sheng Y; Wu B; Han L; Wu C; Dong B; Qi Y
Aging (Albany NY); 2020 Nov; 12(21):21559-21581. PubMed ID: 33170151
[TBL] [Abstract][Full Text] [Related]
7. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
9. A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.
Kaufman JM; Yamada T; Park K; Timmers CD; Amann JM; Carbone DP
Cancer Res; 2017 Jan; 77(1):153-163. PubMed ID: 27821489
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
11. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
Jurmeister P; Vollbrecht C; Behnke A; Frost N; Arnold A; Treue D; Rückert JC; Neudecker J; Schweizer L; Klauschen F; Horst D; Hummel M; Dietel M; von Laffert M
Lung Cancer; 2019 Dec; 138():43-51. PubMed ID: 31634654
[TBL] [Abstract][Full Text] [Related]
12. Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression.
Lin CC; Huang YK; Cho CF; Lin YS; Lo CC; Kuo TT; Tseng GC; Cheng WC; Chang WC; Hsiao TH; Lai LC; Shih JY; Liu YH; Chao KSC; Hsu JL; Lee PC; Sun X; Hung MC; Sher YP
Theranostics; 2020; 10(24):10925-10939. PubMed ID: 33042262
[No Abstract] [Full Text] [Related]
13. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
Cai Y; Wu H; Shi X; Dong Y; Chang X; Zhang L; Zhou L; Su D; Yang M
BMC Cancer; 2020 Feb; 20(1):148. PubMed ID: 32093629
[TBL] [Abstract][Full Text] [Related]
15. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.
Wang B; Jing T; Jin W; Chen J; Wu C; Wang M; Liu Y
J Exp Clin Cancer Res; 2020 Aug; 39(1):170. PubMed ID: 32854746
[TBL] [Abstract][Full Text] [Related]
16. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
17. REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.
Sun S; Hu Z; Huang S; Ye X; Wang J; Chang J; Wu X; Wang Q; Zhang L; Hu X; Yu H
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2273-2283. PubMed ID: 31428934
[TBL] [Abstract][Full Text] [Related]
18. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.
Awasthi S; Maity T; Oyler BL; Qi Y; Zhang X; Goodlett DR; Guha U
J Proteomics; 2018 Oct; 189():48-59. PubMed ID: 29660496
[TBL] [Abstract][Full Text] [Related]
19. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
[TBL] [Abstract][Full Text] [Related]
20. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells.
Tada M; Sumi T; Tanaka Y; Hirai S; Yamaguchi M; Miyajima M; Niki T; Takahashi H; Watanabe A; Sakuma Y
Lung Cancer; 2019 Jul; 133():88-95. PubMed ID: 31200834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]